Related Experiment Videos
Chinese consensus on first-line precision therapy for advanced gastric cancer
Xiaotian Zhang1, Weiqi Sheng2, Tong Xie1
1State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Department of GI Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Innovation (Cambridge (Mass.))
|July 9, 2026
Summary
Precision medicine is revolutionizing advanced gastric cancer treatment in China. Standardizing biomarker testing for therapies like immune checkpoint inhibitors is crucial for optimal patient outcomes.
Area of Science:
- Oncology
- Precision Medicine
- Biomarker Discovery
Background:
- Gastric cancer (GC) presents a significant health burden in China, with many patients diagnosed at advanced stages.
- Traditional chemotherapy offers limited efficacy in advanced GC, necessitating novel treatment strategies.
- Advances in understanding GC molecular heterogeneity are driving a shift towards precision medicine.
Purpose of the Study:
- To provide an expert consensus on standardizing biomarker testing for first-line therapy in advanced gastric cancer.
- To address challenges in integrating complex biomarkers and novel agents into clinical practice.
- To enhance the application of precision medicine for advanced GC patients in China.
Main Methods:
- Review of current literature and clinical data on advanced GC biomarkers.
- Expert panel discussion and consensus development on biomarker testing and treatment selection.
- Analysis of emerging targeted therapies and immune checkpoint inhibitors.
Main Results:
- Identification of key predictive biomarkers including HER2, MSI-H, PD-L1, and Claudin 18.2.
- Highlighting the transformative impact of immune checkpoint inhibitors and Claudin 18.2 targeted agents in first-line treatment.
- Acknowledging breakthroughs in Chinese pharmaceutical development for innovative GC therapies.
Conclusions:
- Biomarker-guided strategies are essential for the future management of advanced GC.
- Standardization of biomarker testing is critical to ensure consistent and effective application of precision medicine.
- Addressing inconsistencies in testing and treatment selection will improve patient outcomes and resource utilization.
